Elisabeth Livingstone

Author

Also Known As

E Livingstone, E. Franklin Livingstone, E. Livingstone, Elisabeth Livingstone, Livingstone, Elisabeth, Yoshiyuki Nakamura

327

Publications

Citations

H-Index

Concepts

All Affiliations

German Cancer Research Center Heidelberg University Essen University Hospital Deutschen Konsortium für Translationale Krebsforschung University of Duisburg-Essen

About

Elisabeth Livingstone is an author at German Cancer Research Center specializing in medicine, oncology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	28	48	2.5K
2	Public Health	3	3	94
3	Health Sciences	2	2	79
4	Social Sciences	1	1	27
5	Cell Biology	1	1	26

Elisabeth Livingstone

Publications

5.6K

Citations

H-Index

Page 1

	Year	Citations
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma David Liu, Bastian Schilling, Derek Liu, Nature Medicine	2019	1K
Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma Lisa Zimmer, Julia Vaübel, Peter Mohr, PLoS ONE	2015	286
TERT Promoter Mutation Status as an Independent Prognostic Factor in Cutaneous Melanoma Klaus Griewank, Rajmohan Murali, Joan Anton Puig‐Butillé, JNCI Journal of the National Cancer Institute	2014	251
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial Lisa Zimmer, Elisabeth Livingstone, Jessica C. Hassel, The Lancet Surgical OncologyOncologyMelanomaImmunologyClinical Trials	2020	238
Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective <i>BRAF</i> Inhibition Lisa Zimmer, Uwe Hillen, Elisabeth Livingstone, Journal of Clinical Oncology	2012	224
Conjunctival Melanomas Harbor <i>BRAF</i> and <i>NRAS</i> Mutations and Copy Number Changes Similar to Cutaneous and Mucosal Melanomas Klaus Griewank, Henrike Westekemper, Rajmohan Murali, Clinical Cancer Research	2013	220
Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity Ralf Gutzmer, Anika Koop, Friedegund Meier, European Journal of Cancer Autoimmune DiseaseIpilimumab-triggered AutoimmunityImmunologyMelanomaCell Death	2017	216
Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy Lars Michel, Iris Helfrich, Ulrike B. Hendgen‐Cotta, European Heart Journal	2021	149
Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns—Results of a non-interventional study of the DeCOG Uwe Hillen, Ulrike Leiter, Sylvie Haase, European Journal of Cancer MedicineCancer ManagementPatient ProfilesRetrospective AnalysisPathology	2018	121
Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma Selma Ugurel, Dirk Schadendorf, Kai Horny, Annals of Oncology Cancer ImmunosurveillanceMedicineMelanomaImmunologyMetastatic Melanoma	2020	108

Page 1